This application is the U.S. national phase of International Application No. PCT/FI2020/050769 filed Nov. 17, 2020 which designated the U.S. and claims priority to Finnish Patent Application No. 20205085 filed Jan. 29, 2020, the entire contents of each of which are hereby incorporated by reference.
The present invention relates to systems and methods to produce particles of organic substances, in particular nano sized and micro sized active pharmaceutical ingredients in the aid of dry ice formation.
In the pharmaceutical industry, large number of drugs are insoluble or poorly soluble in water, which leads to a low dissolution rates and thus also low bioavailability of the drugs. One solution is to reduce particle size which leads to an improvement of the dissolution behavior. The Rapid Expansion of Supercritical Solution (RESS) is among the most used methods. Controlled Expansion of Supercritical Solutions (CESS) in turn, represents an improvement over RESS technologies due to the employment of controlled mass transfer, flow and pressure reduction.
In a typical RESS process, supercritical fluid is used to dissolve solid material under high pressure and temperature, thus forming a homogeneous supercritical phase. Thereafter, the solution is expanded through a nozzle and small particles are formed.
A system suitable for production of micro- and nanoparticles of organic substances using RESS and CESS technologies is shown in
When the mixture expands rapidly through a nozzle into ambient pressure, small particles a of the organic substance are formed, and solid CO2 initially formed sublimates and exits the system via an exhaust vent 106. Since the nozzle is typically attached straight to the collection chamber, the particles are prone exit the collection chamber also.
Accordingly, there is need for further systems and methods to produce micro- and nanoparticles.
The following presents a simplified summary in order to provide a basic understanding of some aspects of various embodiments of the invention. The summary is not an extensive overview of the invention. It is neither intended to identify key nor critical elements of the invention, nor to delineate the scope of the invention. The following summary merely presents some concepts of the invention in a simplified form as a prelude to a more detailed description of exemplifying embodiments of the invention.
It was observed that when a system for producing particles of organic substances was equipped with an extension member between a nozzle and a collection chamber, loss of the particles of organic substances with gaseous CO2 from the system could be avoided or at least alleviated.
Accordingly, it is an aspect of the present invention to provide a new system for producing particles of organic substances, the system comprising
It is also an aspect of the present invention to provide a method for producing particles of organic substances using the disclosed system.
A number of exemplifying and non-limiting embodiments of the invention are also described and claimed.
Various exemplifying and non-limiting embodiments of the invention and to methods of operation, together with additional objects and advantages thereof, are best understood from the following description of specific exemplifying embodiments when read in connection with the accompanying figures.
The verbs “to comprise” and “to include” are used in this document as open limitations that neither exclude nor require the existence of also unrecited features. The features recited in depending claims are mutually freely combinable unless otherwise explicitly stated. Furthermore, it is to be understood that the use of “a” or “an”, i.e. a singular form, throughout this document does not exclude a plurality.
The exemplifying and non-limiting embodiments of the invention are explained in greater detail below with reference to the accompanying figures, in which
The specific examples provided in the description given below should not be construed as limiting the scope and/or the applicability of the appended claims. Lists and groups of examples provided in the description given below are not exhaustive unless otherwise explicitly stated.
System of
The system comprises also an extension member 207 engaged to the outlet tube and the collection chamber. Outer surface of the extension member is preferably coated with insulating material. The nozzle is positioned within the extension member. The nozzle is adapted to allow expansion of the mixture from the outlet tube towards the collection chamber. When the system is in operation, solid carbon dioxide as snow comprising particles of the organic substance a is formed in the extension member. When the carbon dioxide snow sublimates, it exits the system via an exit vent 206 while the particles formed remain in the system.
The system 400 comprises also mechanical means 408 adapted to hold the carbon dioxide snow comprising the particles of organic substance in proximity of the nozzle and the extension member. Exemplary mechanical means are a screw conveyor and shutter comprising energy storing means, such as a spring-loaded shutter.
According to another embodiment the present invention concerns a method for producing particles of organic substances by using a system described above. According to an exemplary non-limiting embodiment the method comprises the following steps
According to a particular embodiment the step b) comprises decreasing the first pressure to a second pressure (P2) during the passing. The decreasing is preferably gradual.
Step c) comprises decreasing the second pressure to the final pressure (PF). The ratio (P1)/(P2) and (P2/PF) is preferably <15, more preferably <10.
Pressure and temperature in the pressure chamber is such that the carbon dioxide is in supercritical state. The final pressure is typically atmospheric pressure. An exemplary temperature in the collection chamber is ambient temperature.
The particle size of organic substances obtained by the method of the present invention is typically 200 nm or less, preferably less than 100 nm, more preferably less than 50 nm, and most preferably less than 20 nm.
As defined herein a “nanoparticle” is a particle whose average diameter is 200 nm or less.
As defined herein an “organic substance” is a molecule containing carbon, excluding carbon containing alloys, and relatively small number of carbon-containing compounds such as metal carbonates and carbonyls, simple oxides of carbon and cyanides, as well as allotropes of carbon and simple carbon halides and sulfides which are considered inorganic. Exemplary organic substrates used in the present technology are biologically active materials including medicaments and their pharmaceutically acceptable organic and inorganic salts.
A non-limiting list of exemplary classes of biologically active materials are active pharmaceutical ingredients that may be of interest include analgesics, antagonists, anti-inflammatory agents, anthelmintics, antianginal agents, antiarrhythmic agents, antibiotics (including penicillins), anticholesterols, anticoagulants, anticonvulsants, antidepressants, antidiabetic agents, antiepileptics, antigonadotropins, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, antipsychotic agents, immunosuppressants, antithyroid agents, antiviral agents, antifungal agents, anxiolytic sedatives (hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, anti-cancer agents, cardiacinotropic agents, contrast media, corticosterioids, cough suppressants (expectorants and mucolytics), diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immunosuppressive and immunoactive agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radiopharmaceuticals, sex hormones (including steroids), anti-allergic agents, stimulants and anorexics, sympathomimetics, thyroid agents, vasidilators, neuron blocking agents, anticholinergic and cholinomimetic agents, antimuscarinic and muscarinic agents, vitamins, and xanthines.
The organic substances, such active pharmaceutical ingredient, may be crystallic, amorphic or their mixtures. According to one embodiment, the nanoparticles comprise active pharmaceutical ingredient and one or more excipients.
Exemplary active pharmaceutical ingredients suitable for the method of the present invention are entacapone, esomeprazole, atorvastatin, rabeprazole, piroxicam and olanzapine. An exemplary active pharmaceutical ingredient is piroxicam (4-hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide).
The combination of the extension member and the nozzle acting as a carbon dioxide snow horn well known in the art. A carbon dioxide snow horn is an orifice that allows expansion of liquid carbon dioxide.
According to another embodiment the present invention concerns new use of carbon dioxide snow horn as collecting means for particles of organic substances. An exemplary carbon dioxide snow horn 509 is shown in
The specific examples provided in the description given above should not be construed as limiting the scope and/or the applicability of the appended claims.
Number | Date | Country | Kind |
---|---|---|---|
20205085 | Jan 2020 | FI | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/FI2020/050769 | 11/17/2020 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2021/152204 | 8/5/2021 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
20020000681 | Gupta et al. | Jan 2002 | A1 |
20030157183 | Perrut | Aug 2003 | A1 |
20040071783 | Hanna et al. | Apr 2004 | A1 |
20060104916 | Shekunov et al. | May 2006 | A1 |
20120021021 | Deschamps et al. | Jan 2012 | A1 |
20140044819 | Demirbüker | Feb 2014 | A1 |
20170231914 | Haeggström et al. | Aug 2017 | A1 |
20180361627 | Merino Lopez | Dec 2018 | A1 |
Number | Date | Country |
---|---|---|
101391156 | Mar 2009 | CN |
2013077459 | May 2013 | WO |
2016055696 | Apr 2016 | WO |
Entry |
---|
Piping and Instrumentation, Gemini Valve, https://www.geminivalve.com/pid-valve-symbols/, no date. |
K. Byrappa et al., “Nanoparticles synthesis using supercritical fluid technology—towards biomedical applications”, Advanced Drug Delivery Reviews, vol. 60, No. 3, Mar. 2008, pp. 299-327 (29 pages). |
Search Report for FI Application No. 20205085 dated Aug. 20, 2020, 2 pages. |
International Search Report for PCT/FI2020/050769 dated Mar. 1, 2021, 4 pages. |
Written Opinion of the ISA for PCT/FI2020/050769 dated Mar. 1, 2021, 6 pages. |
International Preliminary Report on Patentability for PCT/FI2020/050769 dated May 23, 2022, 5 pages. |
Number | Date | Country | |
---|---|---|---|
20230058525 A1 | Feb 2023 | US |